909 related articles for article (PubMed ID: 23477907)
1. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome.
Kim JJ; Chae SJ; Choi YM; Hwang KR; Song SH; Yoon SH; Kim SM; Ku SY; Kim SH; Kim JG; Moon SY
Hum Reprod; 2013 May; 28(5):1354-60. PubMed ID: 23477907
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction in obese Hispanic women with polycystic ovary syndrome.
Sam S; Scoccia B; Yalamanchi S; Mazzone T
Hum Reprod; 2015 Jun; 30(6):1358-64. PubMed ID: 25857311
[TBL] [Abstract][Full Text] [Related]
4. Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome.
Hernández-Mijares A; Bañuls C; Gómez-Balaguer M; Bergoglio M; Víctor VM; Rocha M
Eur J Clin Invest; 2013 Jun; 43(6):549-56. PubMed ID: 23528141
[TBL] [Abstract][Full Text] [Related]
5. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp.
Stepto NK; Cassar S; Joham AE; Hutchison SK; Harrison CL; Goldstein RF; Teede HJ
Hum Reprod; 2013 Mar; 28(3):777-84. PubMed ID: 23315061
[TBL] [Abstract][Full Text] [Related]
6. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS.
Phelan N; O'Connor A; Kyaw-Tun T; Correia N; Boran G; Roche HM; Gibney J
J Clin Endocrinol Metab; 2010 Aug; 95(8):3933-9. PubMed ID: 20519354
[TBL] [Abstract][Full Text] [Related]
8. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.
Rizzo M; Berneis K; Hersberger M; Pepe I; Di Fede G; Rini GB; Spinas GA; Carmina E
Hum Reprod; 2009 Sep; 24(9):2286-92. PubMed ID: 19454589
[TBL] [Abstract][Full Text] [Related]
9. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.
Rees E; Coulson R; Dunstan F; Evans WD; Blundell HL; Luzio SD; Dunseath G; Halcox JP; Fraser AG; Rees DA
Hum Reprod; 2014 Sep; 29(9):2041-9. PubMed ID: 25035436
[TBL] [Abstract][Full Text] [Related]
10. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome.
Ujvari D; Hulchiy M; Calaby A; Nybacka Å; Byström B; Hirschberg AL
Hum Reprod; 2014 Jul; 29(7):1526-35. PubMed ID: 24842895
[TBL] [Abstract][Full Text] [Related]
11. The contribution of diet, physical activity and sedentary behaviour to body mass index in women with and without polycystic ovary syndrome.
Moran LJ; Ranasinha S; Zoungas S; McNaughton SA; Brown WJ; Teede HJ
Hum Reprod; 2013 Aug; 28(8):2276-83. PubMed ID: 23771201
[TBL] [Abstract][Full Text] [Related]
12. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
13. Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors.
Carmina E; Campagna AM; Lobo RA
Hum Reprod; 2013 Aug; 28(8):2245-52. PubMed ID: 23595974
[TBL] [Abstract][Full Text] [Related]
14. LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome.
Doi SA; Abbas JM; Parkinson L; Chakraborty J; Akanji AO
Am J Clin Pathol; 2008 May; 129(5):802-10. PubMed ID: 18426742
[TBL] [Abstract][Full Text] [Related]
15. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.
Berneis K; Rizzo M; Lazzarini V; Fruzzetti F; Carmina E
J Clin Endocrinol Metab; 2007 Jan; 92(1):186-9. PubMed ID: 17062762
[TBL] [Abstract][Full Text] [Related]
16. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Macut D; Panidis D
Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
[TBL] [Abstract][Full Text] [Related]
17. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters.
Pirwany IR; Fleming R; Greer IA; Packard CJ; Sattar N
Clin Endocrinol (Oxf); 2001 Apr; 54(4):447-53. PubMed ID: 11318779
[TBL] [Abstract][Full Text] [Related]
18. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism.
Castelo-Branco C; Steinvarcel F; Osorio A; Ros C; Balasch J
Gynecol Endocrinol; 2010 Oct; 26(10):736-42. PubMed ID: 20569105
[TBL] [Abstract][Full Text] [Related]
19. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
[TBL] [Abstract][Full Text] [Related]
20. Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS.
Roe A; Hillman J; Butts S; Smith M; Rader D; Playford M; Mehta NN; Dokras A
J Clin Endocrinol Metab; 2014 May; 99(5):E841-7. PubMed ID: 24512495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
